ZLAB - Zai Lab Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
29.38
+0.70 (+2.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close28.68
Open28.87
Bid29.18 x 1100
Ask29.27 x 800
Day's Range28.31 - 29.43
52 Week Range14.29 - 33.86
Volume60,355
Avg. Volume156,448
Market Cap1.714B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.64
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.82
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Zai Lab to Host Analyst & Investor Day on April 30, 2019

    SHANGHAI, China, April 17, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that it will.

  • Did Zai Lab's (NASDAQ:ZLAB) Share Price Deserve to Gain 38%?
    Simply Wall St.21 days ago

    Did Zai Lab's (NASDAQ:ZLAB) Share Price Deserve to Gain 38%?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boo...

  • GlobeNewswirelast month

    Zai Lab Announces Presentations at March Conferences

    SHANGHAI, China, March 12, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of.

  • GlobeNewswirelast month

    Zai Lab Announces Financial Results and Corporate Update for Full Year 2018

    -- Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. EST-- SHANGHAI, China, March 07, 2019 -- Zai Lab Limited (“Zai lab” or the Company) (NASDAQ: ZLAB), a China.

  • Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript

    MGNX earnings call for the period ending December 31, 2018.

  • GlobeNewswire2 months ago

    Zai Lab to Announce Full Year 2018 Financial Results

    SHANGHAI, China, Feb. 21, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, today announced that it will.

  • GlobeNewswire2 months ago

    Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    SHANGHAI, China, Feb. 20, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Tao Fu,.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...

  • MacroGenics stock spikes from positive results of cancer drug trial
    American City Business Journals2 months ago

    MacroGenics stock spikes from positive results of cancer drug trial

    The successful late-stage trial is a big victory for the Rockville biotech, which focuses on antibody-based therapeutics to treat cancer.

  • Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye
    Zacks3 months ago

    Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye

    Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye

  • GlobeNewswire3 months ago

    Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board

    Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of immuno-oncology pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Chen will advise the Company as it continues to advance its pre-clinical, internally-developed oncology pipeline. “It is an honor to welcome a physician-scientist of such stature to join our SAB,” said Dr. Samantha Du, Chairman and Chief Executive Officer of Zai Lab.

  • 5 Stocks With Recent Price Strength to Enhance Your Return
    Zacks3 months ago

    5 Stocks With Recent Price Strength to Enhance Your Return

    Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

  • GlobeNewswire3 months ago

    Priority Review Granted to Zai Lab’s NDA Application for ZEJULA (Niraparib) in China

    Zai Lab Limited (ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA, formally known as CFDA) has granted priority review status to the New Drug Application (NDA) for ZEJULA (niraparib, or ZL-2306) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. Zai Lab in-licensed rights to ZEJULA from Tesaro for China, Hong Kong and Macau as an important, new treatment option for more than 50,000 Chinese patients who suffer from ovarian cancer every year.

  • Moving Average Crossover Alert: Zai Lab Limited
    Zacks3 months ago

    Moving Average Crossover Alert: Zai Lab Limited

    Zai Lab Limited Unsponsored ADR (ZLAB) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

  • Will Zai Lab Continue to Surge Higher?
    Zacks3 months ago

    Will Zai Lab Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Zai Lab Limited (ZLAB).

  • Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line
    American City Business Journals3 months ago

    Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line

    The 17-year-old biotech company, a big player in antibody drug research and development, will focus its cash on a maturing pipeline of experimental drugs while letting go of some longtime employees.

  • GlobeNewswire3 months ago

    Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China

    “Completion of patient enrollment of this pivotal trial is an important milestone for Zai as it further demonstrates our clinical development capabilities and commitment to our clinical investigators and ovarian patients in China,” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab. The Phase 3 trial is evaluating niraparib as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer. Recurrent ovarian cancer patients who have responded to a platinum-containing regimen were enrolled in the study and randomized 2:1 to receive either niraparib or placebo once daily.

  • GlobeNewswire4 months ago

    Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme

    Zai Lab (ZLAB) today announced the launch of Optune® (Tumor Treating Fields or TTFields) in Hong Kong for the treatment of glioblastoma multiforme (GBM) with the treatment of its first patient. Hong Kong is the fourth market after the United States, Europe and Japan to have access to this important new medical technology.

  • GlobeNewswire4 months ago

    Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference

    SHANGHAI, China, Dec. 19, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief.

  • Zai Lab Limited (ZLAB): Are Hedge Funds Right About This Stock?
    Insider Monkey4 months ago

    Zai Lab Limited (ZLAB): Are Hedge Funds Right About This Stock?

    While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors are keeping their optimism regarding the current bull run, while still hedging many of their long positions. However, as we know, […]

  • GlobeNewswire4 months ago

    Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA

    Zai Lab Limited (ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ZEJULA (niraparib, or ZL-2306) as a Category 1 drug for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. “The NMPA’s acceptance of our NDA submission for ZEJULA represents a major milestone for Zai Lab as this is our first ever NDA submission in Mainland China,” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.

  • George Soros Bought These 2 Healthcare Stocks in the Third Quarter
    Motley Fool5 months ago

    George Soros Bought These 2 Healthcare Stocks in the Third Quarter

    The Soros Fund Management bought shares of both Express Scripts and Zai Lab Limited during the third quarter.

  • GlobeNewswire5 months ago

    MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China

    Margetuximab, an immune-optimized anti-HER2 monoclonal antibody currently being evaluated in Phase 3 metastatic breast cancer with anticipated topline results in the first quarter of 2019. Zai Lab obtains regional development and commercialization rights for these programs in mainland China, Hong Kong, Macau and Taiwan.

  • GlobeNewswire5 months ago

    Zai Lab and Novocure Awarded Deal of the Year

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, and Novocure Limited (NVCR) today announced that they have received the Deal of the Year Award at the 9th Annual BayHelix Awards Lunch Banquet held during the annual BioCentury-BayHelix China Healthcare Summit in Shanghai, China. The annual award recognizes a groundbreaking collaboration, technology transfer, licensing, capital raising, M&A or joint venture that involves a Chinese company in the healthcare sector. In September of this year, Zai Lab and Novocure announced a strategic collaboration and an exclusive license agreement in the field of oncology by which Zai lab would develop and launch Novocure’s Tumor Treating Fields (TTFields) technology, under the brand name Optune®, in Greater China and to collaborate with Novocure in the global development of the product.  TTFields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.

  • GlobeNewswire5 months ago

    Zai Lab Limited Announces Presentations at November Conferences

    SHANGHAI, China, Nov. 07, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that members of the senior management.